Variant histology, IgD and CD30 expression in low‐risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children’s Oncology Group
dc.contributor.author | Untanu, Ramona Vesna | |
dc.contributor.author | Back, Jason | |
dc.contributor.author | Appel, Burton | |
dc.contributor.author | Pei, Qinglin | |
dc.contributor.author | Chen, Lu | |
dc.contributor.author | Buxton, Allen | |
dc.contributor.author | Hodgson, David C. | |
dc.contributor.author | Ehrlich, Peter F. | |
dc.contributor.author | Constine, Louis S. | |
dc.contributor.author | Schwartz, Cindy L. | |
dc.contributor.author | Hutchison, Robert E. | |
dc.date.accessioned | 2017-12-15T16:48:27Z | |
dc.date.available | 2019-03-01T21:00:17Z | en |
dc.date.issued | 2018-01 | |
dc.identifier.citation | Untanu, Ramona Vesna; Back, Jason; Appel, Burton; Pei, Qinglin; Chen, Lu; Buxton, Allen; Hodgson, David C.; Ehrlich, Peter F.; Constine, Louis S.; Schwartz, Cindy L.; Hutchison, Robert E. (2018). "Variant histology, IgD and CD30 expression in low‐risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children’s Oncology Group." Pediatric Blood & Cancer 65(1): n/a-n/a. | |
dc.identifier.issn | 1545-5009 | |
dc.identifier.issn | 1545-5017 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/139999 | |
dc.description.abstract | BackgroundHistologic prognostic factors have been described for nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). This study examines histologic and immunophenotypic variants in a clinical trial for pediatric NLPHL.ProcedureOne hundred sixty‐eight cases of localized NLPHL were examined for histologic variants, CD30 and immunoglobulin D (IgD) expression, and outcome. Histologic types were scored categorically as 0 = 0, 1 ≤ 25%, and 2 > 25% of the sample.ResultsFifty‐eight (35.1%) cases showed only typical nodular with or without serpiginous histology (types A and B). The remainder showed mixtures of histologies. The numbers of patients with score 2 are 85 (50.6%) type A, 21 (12.5%) type B, 46 (27.4%) with extranodular large B cells (type C), 3 with T‐cell‐rich nodular pattern (type D), 55 (32.7%) with diffuse T‐cell‐rich (type E) pattern, and 2 (1.2%) with diffuse B‐cell pattern (type F). Higher level of types C (P = 0.048) and D (P = 0.033) resulted in lower event‐free survival (EFS). Cytoplasmic IgD was found in 65 of 130 tested (50%), did not significantly associate with EFS but positively correlated with types C and E histology (P < 0.0001) and negatively correlated with types A (P = 0.0003) and B (P = 0.006). Seventeen (10%) expressed CD30, with no adverse effect.ConclusionsVariant histology is common in pediatric NLPHL, especially types C and E, which are associated with IgD expression. Type C variant histology and possibly type D are associated with decreased EFS, but neither IgD nor CD30 are adverse features. Variant histology may warrant increased surveillance, but did not affect overall survival. | |
dc.publisher | IARC | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | children | |
dc.subject.other | histology | |
dc.subject.other | Hodgkin | |
dc.subject.other | lymphoma | |
dc.subject.other | pathology | |
dc.title | Variant histology, IgD and CD30 expression in low‐risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children’s Oncology Group | |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Pediatrics | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/139999/1/pbc26753_am.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/139999/2/pbc26753.pdf | |
dc.identifier.doi | 10.1002/pbc.26753 | |
dc.identifier.source | Pediatric Blood & Cancer | |
dc.identifier.citedreference | Hartmann S, Eichenauer DA, Plütschow A, et al. Histopathological features and their prognostic impact in nodular lymphocyte‐predominant Hodgkin lymphoma—a matched pair analysis from the German Hodgkin Study Group (GHSG). Br J Haematol. 2014; 167 ( 2 ): 238 – 242. | |
dc.identifier.citedreference | Fanale M. A novel prognostic scoring system for NLPHL. Blood. 2013; 122 ( 26 ): 4154 – 4155. | |
dc.identifier.citedreference | Shankar AG, Kirkwood AA, Hall GW, Hayward J, O’Hare P, Ramsay AD. Childhood and adolescent nodular lymphocyte predominant Hodgkin lymphoma—a review of clinical outcome based on the histological variants. Br J Haematol. 2015; 171: 254 – 262. | |
dc.identifier.citedreference | Shet T, Panjwani P, Epari S, et al. A simplified M scoring system to document variant patterns in nodular lymphocyte predominant Hodgkin lymphoma. Leuk Lymph. 2015; 56: 1651 – 1658. | |
dc.identifier.citedreference | Ranjan P, Naresh KN. CD30 expression in L&H cells of Hodgkin’s disease, nodular lymphocyte predominant type. Histopathology. 2003; 42 ( 4 ): 406 – 407. | |
dc.identifier.citedreference | Seliem RM, Ferry JA, Hasserjian RP, Narris NL, Zukerberg LR. Nodular lymphocyte‐predominant Hodgkin lymphoma (NLPHL) with CD30‐positive lymphocyte‐predominant (LP) cells. J Hematopathol. 2011; 4: 175 – 181. | |
dc.identifier.citedreference | Prakash S, Fountaine T, Raffeld M, Jaffe ES, Pittaluga S. IgD positive L&H cells identify a unique subset of nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol. 2006; 30 ( 5 ): 585 – 592. | |
dc.identifier.citedreference | O’Sullivan CC, Ozdemirli M, Bazylewicz M, Cheson BD. Complete response to brentuximab vedotin in a transplant‐naïve patient with relapsed CD30‐positive nodular lymphocyte‐predominant Hodgkin lymphoma. Clin Adv Hematol Oncol. 2013; 11 ( 6 ): 382 – 385. | |
dc.identifier.citedreference | Wang S, Medeiros LJ, Xu‐Monette ZY, et al. Epstein‐Barr virus‐positive nodular lymphocyte predominant Hodgkin lymphoma. Ann Diagn Pathol. 2014; 18 ( 4 ): 203 – 209. | |
dc.identifier.citedreference | Huppmann AR, Nicolae A, Slack GW, et al. EBV may be expressed in the LP cells of nodular lymphocyte‐predominant Hodgkin lymphoma (NLPHL) in both children and adults. Am J Surg Pathol. 2014; 38 ( 3 ): 316 – 324. | |
dc.identifier.citedreference | Appel BE, Chen L, Buxton AB, et al. Minimal treatment of low‐risk pediatric lymphocyte predominant Hodgkin lymphoma: a report from the Children’s Oncology Group. J Clin Oncol. 2016; 34: 2372 – 2379. | |
dc.identifier.citedreference | Swerdlow SH, Campo E, Harris NL, et al,, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon; 2008. | |
dc.identifier.citedreference | Anagnostopoulos I, Hansmann ML, Franssila K, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000; 96 ( 5 ): 1889 – 1899. | |
dc.identifier.citedreference | Nicholas DS, Harris S, Wright DH. Lymphocyte predominance Hodgkin’s disease—an immunohistochemical study. Histopathology. 1990 16 ( 2 ): 157 – 165. | |
dc.identifier.citedreference | Poppema S, Delsol G, Pileri SA, et al. Nodular lymphocyte predominant Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon; 2008: 323 – 325. | |
dc.identifier.citedreference | Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA. Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003; 27 ( 10 ): 1346 – 1356. | |
dc.identifier.citedreference | Wilder RB, Schlembach PJ, Jones D, et al. European Organization for Research and Treatment of Cancer and Groupe d’Etude des Lymphomes de l’Adulte very favorable and favorable, lymphocyte‐predominant Hodgkin disease. Cancer. 2002; 94 ( 6 ): 1731 – 1738. | |
dc.identifier.citedreference | Xing KH, Connors JM, Lai A, et al. Advanced‐stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. Blood. 2014; 123 ( 23 ): 3567 – 3573. | |
dc.identifier.citedreference | Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127 ( 20 ): 2375 – 2390. | |
dc.identifier.citedreference | Hartmann S, Eichenauer DA, Plütschow A, et al. The prognostic impact of variant histology in nodular lymphocyte‐predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2013; 122 ( 26 ): 4246 – 4242. | |
dc.identifier.citedreference | Fanale M. Lymphocyte‐predominant Hodgkin lymphoma: what is the optimal treatment? Hematol Am Soc Hematol Educ Program. 2013; 2013: 406 – 413. | |
dc.identifier.citedreference | Karayalcin G, Behm FG, Gieser PW, et al. Lymphocyte predominant Hodgkin disease: clinico‐pathologic features and results of treatment—the Pediatric Oncology Group experience. Med Pediatr Oncol. 1997; 29 ( 6 ): 519 – 525. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.